A Two-Part Phase 2a Study in Patients With End-Stage Renal Disease Treated With Hemodialysis; Part A is an Open-Label Study Arm to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of 100 mg RVX000222; and Part B is a Double-Blind, Randomized, Placebo-Controlled, Sequential Cross-Over Study Arm to Evaluate the Efficacy, Safety, and Pharmacokinetics of RVX000222
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Feb 2018
At a glance
- Drugs Apabetalone (Primary)
- Indications Renal failure
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Resverlogix Corporation
- 08 Feb 2018 According to a Resverlogix media release, company expects to randomize its first patient during the second quarter of 2018.
- 13 Dec 2017 Planned End Date changed from 15 Jul 2018 to 15 May 2019.
- 13 Dec 2017 Planned primary completion date changed from 15 Jul 2018 to 15 May 2019.